FM
REGN icon

Family Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Family Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-200
Closed -$112K – 194
2021
Q2 		$112K Buy
+200
New +$101K 0.03% 185
2020
Q1 		– Sell
-600
Closed -$225K – 186
2019
Q4 		$225K Sell
600
-1,200
-67% -$404K 0.08% 135
2019
Q3 		$499K Hold
1,800
– – 0.19% 87
2019
Q2 		$563K Buy
+1,800
New +$599K 0.22% 83

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Family Management's REGN Position: Q1 2026 in Review

Family Management increased its Regeneron Pharmaceuticals (REGN) stake by 306% in Q1 2026, buying an estimated $2.19M and bringing the position to 3,794 shares worth $2.93M. The position accounts for 0.35% of the portfolio, ranked #72.

Family Management first reported a position in REGN in Q4 2018 and has held it in 30 quarters since. The position peaked at $6.99M in Q2 2024. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Family Management held 3,794 shares of Regeneron Pharmaceuticals worth $2.93M as of Q1 2026.
  • Family Management bought 2,859 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $2.19M.
  • Regeneron Pharmaceuticals made up 0.35% of Family Management's portfolio in Q1 2026, its #72 holding.
  • Family Management first reported a position in Regeneron Pharmaceuticals in Q4 2018 and has held it in 30 quarters since.
  • Family Management's Regeneron Pharmaceuticals position peaked at $6.99M in Q2 2024.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Family Management's 13F filing for Q1 2026, filed 15 May 2026.